GH

Guardant Health, Inc.

29.87 USD
-0.63 (-2.07%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Guardant Health, Inc. stock is up 20.59% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 5 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
04 Jun 18:18 21 Jun, 2024 25.00 CALL 150 7208
05 Jun 15:43 17 Jan, 2025 30.00 CALL 100 1678
05 Jun 15:47 21 Jun, 2024 25.00 CALL 100 7057
05 Jun 15:51 19 Jul, 2024 35.00 CALL 400 645
05 Jun 16:30 19 Jul, 2024 30.00 PUT 232 72
05 Jun 17:16 21 Jun, 2024 30.00 CALL 200 4608
05 Jun 18:19 21 Jun, 2024 22.50 CALL 30 5858
05 Jun 18:39 21 Jun, 2024 25.00 CALL 50 7057
05 Jun 18:58 21 Jun, 2024 30.00 CALL 200 4608
05 Jun 19:15 21 Jun, 2024 25.00 CALL 50 7057

About Guardant Health, Inc.

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, LDT, CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible. Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients.

  • Canaccord Genuity
    Tue Jun 4, 09:54
    buy
    confirm
  • Jefferies
    Mon Jun 3, 14:07
    buy
    initial
  • Stephens & Co.
    Fri May 24, 11:38
    buy
    confirm